Literature DB >> 19672103

The PDE1A-PKCalpha signaling pathway is involved in the upregulation of alpha-smooth muscle actin by TGF-beta1 in adventitial fibroblasts.

Hai-Yan Zhou1, Wen-Dong Chen, Ding-Liang Zhu, Ling-Yun Wu, Jia Zhang, Wei-Qing Han, Jian-Dong Li, Chen Yan, Ping-Jin Gao.   

Abstract

BACKGROUND: Increasing evidence has suggested that differentiation of adventitial fibroblasts (AFs) to myofibroblasts plays an important role in arterial remodeling. The molecular mechanisms by which myofibroblast formation is regulated still remain largely unknown. This study aimed to evaluate the role of cyclic nucleotide phosphodiesterase 1A (PDE1A) in the formation of adventitial myofibroblasts induced by transforming growth factor (TGF)-beta(1). METHODS AND
RESULTS: AFs were cultured by the explant method. Western blot and immunocytochemistry were applied for alpha-smooth muscle actin (SMA) or protein kinase C (PKC) alpha protein analysis. Results showed that TGF-beta(1) upregulated PDE1A protein expression in rat aortic AFs and pharmacological inhibition of PDE1A blocked TGF-beta(1)-induced alpha-SMA expression, a marker of myofibroblast formation, suggesting that the upregulation of PDE1A may mediate TGF-beta(1)-induced AF transformation. Moreover, calphostin C (a PKC inhibitor) inhibited TGF-beta(1)-induced alpha-SMA expression, whereas phorbol-12-myristate-13-acetate (a PKC activator) induced it. Finally, the upregulation of PKCalpha expression by TGF-beta(1) was also inhibited by PDE1A inhibition.
CONCLUSIONS: Taken together, our data suggest that TGFbeta(1) induces alpha-SMA expression and myofibroblast formation via a PDE1A-PKCalpha-dependent mechanism. Our study thus unveils a novel signaling mechanism underlying TGF-beta(1)-induced adventitial myofibroblast formation. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19672103      PMCID: PMC2855283          DOI: 10.1159/000231716

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  25 in total

1.  Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.

Authors:  John Wharton; Julian W Strange; Gigi M O Møller; Ellena J Growcott; Xiaohui Ren; Angela P Franklyn; Stephen C Phillips; Martin R Wilkins
Journal:  Am J Respir Crit Care Med       Date:  2005-04-07       Impact factor: 21.405

2.  Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts.

Authors:  J Redondo; J E Bishop; M R Wilkins
Journal:  Br J Pharmacol       Date:  1998-08       Impact factor: 8.739

3.  NAD(P)H oxidase-derived reactive oxygen species regulate angiotensin-II induced adventitial fibroblast phenotypic differentiation.

Authors:  Wei-Li Shen; Ping-Jin Gao; Zai-Qian Che; Kai-Da Ji; Ming Yin; Chen Yan; Bradford C Berk; Ding-Liang Zhu
Journal:  Biochem Biophys Res Commun       Date:  2005-11-15       Impact factor: 3.575

4.  Type VI collagen induces cardiac myofibroblast differentiation: implications for postinfarction remodeling.

Authors:  Jennifer E Naugle; Erik R Olson; Xiaojin Zhang; Sharon E Mase; Charles F Pilati; Michael B Maron; Hans G Folkesson; Walter I Horne; Kathleen J Doane; J Gary Meszaros
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-09-02       Impact factor: 4.733

5.  Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension.

Authors:  Oleg V Evgenov; Cornelius J Busch; Natalia V Evgenov; Rong Liu; Bodil Petersen; George E Falkowski; Beata Petho; Adám Vas; Kenneth D Bloch; Warren M Zapol; Fumito Ichinose
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-11-11       Impact factor: 5.464

Review 6.  The role of natriuretic peptides in cardioprotection.

Authors:  Toshio Nishikimi; Nobuyo Maeda; Hiroaki Matsuoka
Journal:  Cardiovasc Res       Date:  2005-11-10       Impact factor: 10.787

7.  PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis.

Authors:  Heather A Burgess; Louis Eugene Daugherty; Thomas H Thatcher; Heather F Lakatos; Denise M Ray; Michelle Redonnet; Richard P Phipps; Patricia J Sime
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-02-25       Impact factor: 5.464

8.  Nitric oxide regulates transforming growth factor-beta signaling in endothelial cells.

Authors:  Marta Saura; Carlos Zaragoza; Beatrice Herranz; Mercedes Griera; Luisa Diez-Marqués; Diego Rodriguez-Puyol; Manuel Rodriguez-Puyol
Journal:  Circ Res       Date:  2005-10-20       Impact factor: 17.367

9.  Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling.

Authors:  Dongsoo Kim; Toru Aizawa; Heng Wei; Xinchun Pi; Sergei D Rybalkin; Bradford C Berk; Chen Yan
Journal:  J Mol Cell Cardiol       Date:  2004-12-08       Impact factor: 5.000

10.  Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival.

Authors:  David J Nagel; Toru Aizawa; Kye-Im Jeon; Weimin Liu; Amy Mohan; Heng Wei; Joseph M Miano; Vincent A Florio; Pingjin Gao; Vyacheslav A Korshunov; Bradford C Berk; Chen Yan
Journal:  Circ Res       Date:  2006-03-02       Impact factor: 17.367

View more
  17 in total

Review 1.  PDE1 isozymes, key regulators of pathological vascular remodeling.

Authors:  Stefan Chan; Chen Yan
Journal:  Curr Opin Pharmacol       Date:  2011-09-29       Impact factor: 5.547

Review 2.  Atrial remodeling, fibrosis, and atrial fibrillation.

Authors:  José Jalife; Kuljeet Kaur
Journal:  Trends Cardiovasc Med       Date:  2014-12-31       Impact factor: 6.677

3.  Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart.

Authors:  Clint L Miller; Yujun Cai; Masayoshi Oikawa; Tamlyn Thomas; Wolfgang R Dostmann; Manuela Zaccolo; Keigi Fujiwara; Chen Yan
Journal:  Basic Res Cardiol       Date:  2011-10-20       Impact factor: 17.165

4.  Quantification of uncertainty in a new network model of pulmonary arterial adventitial fibroblast pro-fibrotic signalling.

Authors:  Ariel Wang; Shulin Cao; Yasser Aboelkassem; Daniela Valdez-Jasso
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2020-05-25       Impact factor: 4.226

5.  Dynamic expression of proteins associated with adventitial remodeling in adventitial fibroblasts from spontaneously hypertensive rats.

Authors:  Shu-jie Guo; Tai-rong Wang; Jing Chen; Ling-yun Wu; Ping-jin Gao; Ding-liang Zhu
Journal:  Acta Pharmacol Sin       Date:  2010-08-30       Impact factor: 6.150

6.  The tunica adventitia of human arteries and veins as a source of mesenchymal stem cells.

Authors:  Mirko Corselli; Chien-Wen Chen; Bin Sun; Solomon Yap; J Peter Rubin; Bruno Péault
Journal:  Stem Cells Dev       Date:  2011-10-18       Impact factor: 3.272

Review 7.  Vascular Smooth Muscle Remodeling in Conductive and Resistance Arteries in Hypertension.

Authors:  Isola A M Brown; Lukas Diederich; Miranda E Good; Leon J DeLalio; Sara A Murphy; Miriam M Cortese-Krott; Jennifer L Hall; Thu H Le; Brant E Isakson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-09       Impact factor: 8.311

8.  Effect of CTRP3 on activation of adventitial fibroblasts induced by TGF-β1 from rat aorta in vitro.

Authors:  Shaohui Lin; Shaojun Ma; Ping Lu; Wenwei Cai; Yi Chen; Jing Sheng
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

9.  Fish oil selectively improves heart function in a mouse model of lipid-induced cardiomyopathy.

Authors:  Raffay S Khan; Aalap Chokshi; Konstantinos Drosatos; Hongfeng Jiang; Shuiqing Yu; Collette R Harris; P Christian Schulze; Shunichi Homma; William S Blaner; Gerald I Shulman; Li-Shin Huang; Ira J Goldberg
Journal:  J Cardiovasc Pharmacol       Date:  2013-04       Impact factor: 3.105

10.  Morphoproteomics provides support for TGF-β pathway signaling in the osteoclastogenesis and immune dysregulation of osteolytic Langerhans cell histiocytosis.

Authors:  Sanda Alexandrescu; Nina Tatevian; Bogdan A Czerniak; Michael H Covinsky; Nadja K Burns; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2012-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.